Gastric Cancer — DX-8951f in Treating Patients With Metastatic Stomach Cancer
Citation(s)
A Phase II Study Of Intravenous Exatecan Mesylate (DX-891F) Administered Daily For Five Days Every Three Weeks To Patients With Previously Untreated Metastatic Gastric Cancer